Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
1370 Views
eMediNexus 03 July 2018
Findings of a new study presented June 24, 2018 at the 78th Scientific Sessions of the American Diabetes Association in Orlando, Florida show that addition of sotagliflozin 200/400 mg to optimized insulin therapy lowers HbA1c, body weight and the incidence of severe hypoglycemia after a year of treatment in patients with type 1 diabetes.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}..
Low FT3: A Novel Potentially Modifiable Risk Factor for Diabetic Neu.....
How Anemia Types Alter HbA1c Values..
Optimizing Glycemic Control in GDM: Continuous Glucose Monitoring Vs C.....
Factors Driving the Atopic March in Children with Early-Onset Atopic .....
Metabolic Health: Another Piece in the Parkinson Puzzle?..
{{Article_Title}}..
South Asian Nations Push for Collaborative Public Health Research..
Health Ministry Mandates Excipient Disclosure on Drug Labels from 2026..
Israel to Perform World's First Human Spinal Cord Implant..
Madras High Court Seeks Report On Kidney Trafficking Racket in Tamil Nadu..
ICMR Study Shows Nutrition Support Cuts TB Risk, Influences WHO Policy..